The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) is a huge mover today! The stock increased 6.08% or $0.86 during the last trading session, hitting $15. About 322,922 shares traded hands or 53.32% up from the average. Aimmune Therapeutics Inc (NASDAQ:AIMT) has declined 16.48% since February 26, 2016 and is downtrending. It has underperformed by 26.90% the S&P500.
The move comes after 8 months positive chart setup for the $582.34M company. It was reported on Sep, 30 by Barchart.com. We have $20.25 PT which if reached, will make NASDAQ:AIMT worth $203.82M more.
Analysts await Aimmune Therapeutics Inc (NASDAQ:AIMT) to report earnings on November, 2. They expect $-0.44 EPS, down 22.22% or $0.08 from last year’s $-0.36 per share. After $-0.43 actual EPS reported by Aimmune Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.33% negative EPS growth.
Aimmune Therapeutics Inc (NASDAQ:AIMT) Ratings Coverage
Out of 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aimmune Therapeutics has been the topic of 5 analyst reports since August 31, 2015 according to StockzIntelligence Inc. The rating was initiated by Bank of America with “Buy” on Monday, August 31. On Monday, August 31 the stock rating was initiated by Piper Jaffray with “Overweight”. The firm has “Outperform” rating given on Monday, August 31 by Credit Suisse. The company was initiated on Monday, September 26 by JMP Securities. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, November 17.
According to Zacks Investment Research, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.”
More recent Aimmune Therapeutics Inc (NASDAQ:AIMT) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on August 06, 2015. Also Fiercebiotech.com published the news titled: “Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101” on June 18, 2015. Businesswire.com‘s news article titled: “Aimmune Therapeutics Announces COO Transition” with publication date: October 09, 2015 was also an interesting one.
AIMT Company Profile
Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, incorporated on June 24, 2011, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.